**ERBB2 Copy Number as a Quantitative Biomarker for Real-World Outcomes to Anti-Human Epidermal Growth Factor Receptor 2 Therapy in Advanced Gastroesophageal Adenocarcinoma**

Liangliang Zhang, PhD1; Omar Hamdani, PhD1; Ole Gjerup, PhD1; Cheryl Cho-Phan, MD2; Jeremy Snider, PhD2; Emily Castellanos, MD, MPH2; Halla Nimeiri, MD1; Garrett Frampton, PhD1; Jeffrey M. Venstrom, MD1; Geoffrey Oxnard, MD1; Samuel J. Klempner, MD3; and Alexa B. Schrock, PhD1

**PURPOSE**

Human epidermal growth factor receptor 2 (HER2) overexpression or amplification (ERBB2amp) are biomarkers for approved anti-HER2 therapies. ERBB2amp may better predict response compared with immunohistochemistry or in situ hybridization, and quantitative copy number (CN) may further stratify patients. We characterized ERBB2amp in advanced gastroesophageal adenocarcinomas (GEA) and hypothesized that increased CN was associated with better outcome to trastuzumab.

**METHODS**

Comprehensive genomic profiling, including assessment of ERBB2amp, was performed for 12,905 GEA tissue cases. Clinical outcomes were assessed using a clinicogenomic database linking deidentified electronic health record–derived clinical data to genomic data. Multivariable Cox proportional hazard models were used for real-world progression-free survival (rwPFS) comparisons.

**RESULTS**

ERBB2amp (CN ≥ 5) was detected in 15% (1,934 of 12,905) of GEA; median CN 22 (interquartile range 9-73). Median ERBB2 amplicon size was 0.27 megabase (interquartile range 0.13-0.95), and smaller amplicons were associated with higher CN (P < .001). In the clinicogenomic database, of 101 evaluable first-line trastuzumab-treated patients, ERBB2 CN was a significant predictor of rwPFS as a continuous variable (adjusted hazard ratio = 0.73; 95% CI, 0.60 to 0.89; P = .002), whereas ERBB2CN was not predictive of rwPFS on chemotherapy (adjusted hazard ratio = 0.93; 95% CI, 0.73 to 1.20; P = .59). Among trastuzumab-treated patients, no significant associations with ERBB2 CN were observed for disease site, age, stage at advanced diagnosis, or most selected coalterations.

**CONCLUSION**

ERBB2amp was detected in 15% of GEA tissue samples, with significant diversity in ERBB2 CN and amplicon focality. ERBB2 CN was predictive of rwPFS as a continuous variable for patients treated with trastuzumab. Further studies exploring the clinical utility of quantitative ERBB2CN, particularly in the setting of the evolving anti-HER2 landscape and combination therapies, are warranted.

JCO Precis Oncol 6:e2100330. © 2022 by American Society of Clinical Oncology

**INTRODUCTION**

The ERBB2 gene encodes the human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase (RTK), a member of the epidermal growth factor receptor (EGFR)-related family of RTKs, and ligand-independent activation of HER2 can result from HER2 overexpression or ERBB2 amplification (ERBB2amp). The anti-HER2 therapy trastuzumab is also approved in advanced gastroesophageal adenocarcinoma (advGEA) in combination with first-line chemotherapy on the basis of results from the Trastuzumab for Gastric Cancer trial and investigational use of anti-HER2 therapies is being explored in other tumor types including colorectal cancer.

High concordance for HER2 expression by immunohistochemistry (IHC) or in situ hybridization (ISH) and other modalities, among each other and with and ERBB2amp by next-generation sequencing (NGS), has been demonstrated in GEA; however, in one study evaluating discordant cases, those positive for both expression and amplification had better efficacy outcomes to anti-HER2 therapy compared with those positive for HER2 expression but negative for ERBB2amp. Stein et al and others have also presented data suggesting that
ERBB2 amplification is present in multiple tumor types including 15% of GEA, but the degree of CN gain and amplicon focality is variable. We show that ERBB2 CN is a significant predictor of improved real-world overall survival and real-world progression-free survival as a continuous variable in advanced GEA patients treated with first-line trastuzumab.

Relevance
Genomic profiling to quantitatively assess ERBB2 amplification should be performed to inform treatment selection and trial enrollment in GEA, particularly as new anti-HER2 therapies and combinations continue to be developed.

CONTEXT
Key Objective
Human epidermal growth factor receptor 2 (HER2) overexpression or ERBB2 amplification are established biomarkers in gastroesophageal adenocarcinoma (GEA), and studies have suggested that degree of expression or amplification may further inform outcomes to anti-HER2 therapies. We sought to determine whether quantitative ERBB2 copy number (CN) as determined by next-generation sequencing was directly associated with better outcomes to trastuzumab in a real-world data set of patients with GEA.

Knowledge Generated
ERBB2 amplification is present in multiple tumor types including 15% of GEA, but the degree of CN gain and amplicon focality is variable. We show that ERBB2 CN is a significant predictor of improved real-world overall survival and real-world progression-free survival as a continuous variable in advanced GEA patients treated with first-line trastuzumab.

Relevance
Genomic profiling to quantitatively assess ERBB2 amplification should be performed to inform treatment selection and trial enrollment in GEA, particularly as new anti-HER2 therapies and combinations continue to be developed.

METHODS
Foundation Medicine Comprehensive Genomic Profiling
Hybrid capture–based comprehensive genomic profiling (CGP) was performed on formalin-fixed paraffin-embedded tumor tissue samples collected from 12,905 patients with primarily advanced GEA, as well as a comparison cohort of 34,629 primarily advanced breast cancer patients, during routine clinical care (January 2011-September 2020). Testing was performed in a Clinical Laboratory Improvement Amendments–certified, College of American Pathologists–accredited, New York State–regulated reference laboratory (Foundation Medicine, Inc, Cambridge, MA). Approval for this study, including a waiver of informed consent and a Health Insurance Portability and Accountability Act waiver of authorization, was obtained from the WIRB-Copernicus Group Institutional Review Board (IRB; protocol no. 20152817).

As previously described, DNA (> 50 ng) was extracted from formalin-fixed paraffin-embedded specimens, and NGS was performed by hybridization-captured, adaptor ligation–based libraries to high, uniform coverage (> 500×) for all coding exons of up to 324 cancer-related genes (FoundationOne or FoundationOne CDx) plus selected introns. The results were analyzed for base substitutions (subs), short insertions and deletions (indels), CN gains or losses, and rearrangements. ERBB2 amp was defined as gene CN ≥ 3 of the tumor base ploidy (ie, CN = 5 in diploid, CN = 6 in triploid, CN = 7 in tetraploid, etc) and gene CN of ≥ 5 with 80% of baited targets amplified. For additional methods for tumor mutational burden (TMB) and genomic ancestry determination, see the Data Supplement.

Flatiron Health-Foundation Medicine CGDB
This study used the nationwide deidentified Flatiron Health-Foundation Medicine CGDB (FH-FMI CGDB). Retrospective longitudinal clinical data were derived from electronic health records (EHRs), comprising patient-level structured and unstructured data, curated via technology-enabled abstraction, and were linked to genomic data derived from FMI CGP tests by deidentified, deterministic matching. During the study period, the deidentified data originated from approximately 280 US cancer clinics (approximately 800 sites of care). Genomic alterations were identified via CGP as described above. To date, more than 400,000 samples have been sequenced from patients across the United States. The study included 2,270 patients who had a diagnosis of advGEA, received care within the FH network between January 2011 and
September 2020, and underwent tissue CGP (FoundationOne or FoundationOne CDx). IRB approval with waiver of informed consent was obtained before study conduct from WIRB-Copernicus Group IRB.

Patients who were diagnosed with advanced GEA > 90 days before their first structured activity within the FH network or who received their FMI report > 60 days after their last FH structured activity date were excluded to ensure all therapies received before CGP were captured and to exclude patients who left the FH network before CGP. This left 270 unique patients eligible for this study. Clinical characteristics and treatment information were obtained via technology-enabled abstraction of clinical notes and radiology and pathology reports and linked to CGP data. Real-world progression (rwP) events were captured as episodes in which the treating clinician documented in the EHR that there had been growth or worsening of disease.22,23

The Fisher exact test or chi-squared test was used to assess significance of categorical relationships, and the Kruskal-Wallis test was used to assess significance of continuous variables. False discovery rate correction was performed by the Benjamin-Hochberg procedure to correct P values for multiple tests.

**Outcome Assessment**

The primary study outcome measurement was rwPFS, which was defined as the time from therapy of interest initiation to the first rwP date > 14 days after therapy initiation or to death, and patients were censored at their last clinic note date if no progression or death was observed. Real-world overall survival (rwOS), which was defined as the time from therapy of interest initiation to death, was also measured as secondary outcome. rwPFS and rwOS were compared across different ERBB2 CN subgroups using the Kaplan-Meier method and the log-rank test. Median rwPFS and rwOS values were estimated in months with 95% CIs. Multivariable Cox proportional hazard models were fitted on rwPFS or rwOS to estimate the adjusted hazard ratio and its significance level of ERBB2 CN. Log-transformed CN was used in Cox models. Other items included in the Cox model were age at advanced diagnosis, practice type (academic or community), sex, origin of disease site (esophageal, gastroesophageal junction [GEJ], or gastric), Eastern Cooperative Oncology Group (ECOG) performance status, and therapy line number for rwPFS analysis of chemotherapy only.

**RESULTS**

**Foundation Medicine Genomic Database**

Analysis of the Foundation Medicine genomic database of 12,905 GEA tumor samples (Data Supplement) identified ERBB2amp in 15.0% (n = 1,934) cases including 19.8% (1,384 of 6,975) of esophageal or GEJ adenocarcinomas and 9.3% (550 of 5,930) of gastric adenocarcinomas (Fig 1A). The clinocogenomic characteristics of 1,934 cases of ERBB2amp GEA compared with GEA without ERBB2 alterations (ERBB2wt) are shown in the Data Supplement. For ERBB2-amplified cases, median patient age was 63 years, 82.5% of patients were male, and for 71.6% of cases the primary tumor location was esophageal or GEJ. Both male sex and esophageal tumor location were further enriched relative to ERBB2wt GEA patients. The most frequent coalterated genes with ERBB2amp were TP53 (89.2%), CDKN2A (27.3%), and CCNE1 (19.2%; Data Supplement). Coalteration frequencies were similar for ERBB2amp versus ERBB2wt GEA, although TP53 alterations were significantly more common in ERBB2amp cases (89.2% v 71.2%; P < .001), whereas KRAS alterations were significantly less common in ERBB2amp cases (9.2% v 21.9%; P < .001) and overall gene amplifications were more frequent in the ERBB2amp subset (Data Supplement). High microsatellite instability was rare in ERBB2amp GEA samples (0.3%) compared with ERBB2wt GEA (0.3% v 3.2%; P < .001), whereas TMB distribution was similar regardless of ERBB2 amplification status (median 4.3 v 3.8 mutations per megabase [Mb] Data Supplement).

In ERBB2amp GEA samples, median ERBB2 CN was 22 (interquartile range [IQR] 9-73) and was similar across esophageal or GEJ (median CN = 22, IQR = 9-72) and gastric (median CN = 20.5, IQR = 9-73) subtypes (Fig 1B). We further assessed the size of the ERBB2 amplicon in ERBB2amp GEA cases. The median ERBB2 amplicon size was 0.27 Mb (IQR 0.13-0.95) for all GEA cases and was also similar for esophageal or GEJ (median 0.28 Mb, IQR 0.13-1.26) and gastric (median 0.26 Mb, IQR 0.13-0.85) subtypes. We also examined the correlation between ERBB2 CN and amplicon size in GEA samples and found that more focal amplification significantly correlated with higher CN (P < .001) for amplicons larger than 0.16 Mb (Fig 1C). In an orthogonal comparison, ERBB2 was amplified in 9.2% (3,193 of 34,629) of breast carcinoma cases analyzed, and CN (median 19, IQR 9-40), amplicon size (median 0.32 Mb, IQR 0.13-1.37), and correlation between CN and amplicon focality were similar (Fig 1). In both GEA and breast cases, for amplicons ≤ 0.08 Mb, partial ERBB2 gene amplification was more common and cases with < 100% of bailed ERBB2 targets amplified were associated with lower ERBB2 CN gains (Data Supplement).

**CGDB Outcomes Analysis**

Of 2,270 patients with advGEA in the CGDB, ERBB2amp was detected in 15% (342 of 2,164) of cases with CGP performed on tissue biopsies (Data Supplement). Of 39 evaluable patients with ERBB2amp whose CGP report was obtained before first-line, 66.7% of patients received a first-line treatment regimen containing anti-HER2 therapy (most commonly chemotherapy plus trastuzumab [61.5%]; Fig 2A). No anti-HER2 therapy was included in the first-line treatment regimen in 25.6% of cases including 20.5% of patients who received chemotherapy alone. The remaining 7.7% of
**FIG 1.** ERBB2 amplification frequencies, CN distribution, and amplicon size across GEA samples. (A) Frequency of ERBB2 amplification detected in all GEA tissue samples as well as in esophageal/GEJ and gastric subsets and breast cancer samples in the Foundation Medicine Genomic Database. (B) Similar ERBB2 CN distribution was observed in ERBB2-amplified esophageal/GEJ, gastric, and breast subsets. (C) ERBB2 CN distribution in ERBB2-amplified GEA and breast cancer samples bucketed by ERBB2 amplicon size. For amplicons > 0.16 Mbp, increased focality significantly correlated with higher ERBB2 CN (P < .001). CN, copy number; GEA, gastroesophageal adenocarcinoma; GEJ, gastroesophageal junction; Mbp, megabase pairs.
cases received an unspecified clinical study drug. In the subset of patients who did not receive anti--HER2 therapy in the first-line post-CGP report, the median \( \text{ERBB2} \) CN was 7 (IQR 6-7.5) and a prior negative HER2 IHC or ISH test was recorded in 20% (2 of 10) of cases; of the remaining patients, four had a prior positive HER2 IHC and/or ISH test and four had no documentation of prior HER2 IHC or ISH testing. Furthermore, of the 10 patients with \( \text{ERBB2} \) amp who did not receive anti--HER2 therapy in the first-line post-CGP, only two had documentation of second-line therapy at the time of data cutoff and in both cases that second-line regimen included an anti--HER2 treatment. By contrast, for \( \text{ERBB2} \) wt patients, the most common first-line therapies post-CGP report were chemotherapy alone (63.6%) or other therapies (20.1%) including immunotherapy, non--HER2-targeted therapies, or unspecified clinical study drugs (Fig 2B). Of 10 patients with \( \text{ERBB2} \) wt tumors on CGP who received an anti--HER2 containing regimen in the first-line post-CGP, seven had prior HER2 and/or IHC test results and 7 of 7 results were positive.

Among 270 patients with \( \text{ERBB2} \) amp advGEA meeting criteria for assessment, 101 received anti--HER2 therapy in the first-line setting regardless of CGP report timing (cohort A). A control set (cohort B) of 87 \( \text{ERBB2} \) amp patients treated with chemotherapy alone was also assessed; these patients received chemotherapy in any line because of prohibitively small numbers available for assessment when limited to the first-line setting. Clinical characteristics, genomic characteristics, and therapeutic regimens comparing cohorts A and B are shown in Table 1. Patients with \( \text{ERBB2} \) amplified GEA by CGP who received first-line anti--HER2 therapy (cohort A) were significantly more likely to have had a documented positive HER2 IHC or FISH result than those who received chemotherapy alone in the first-line (82.2% vs 57.9%; \( P < .001 \)) or in any line (cohort B, 82.2% vs 57.5%; \( P < .001 \)).

In patients with \( \text{ERBB2} \) amp advGEA treated with first-line trastuzumab (cohort A), higher \( \text{ERBB2} \) CN was a significant predictor as a continuous variable of longer rwPFS (hazard ratio [HR], 0.73; 95% CI, 0.60 to 0.89; \( P < .01 \)). In contrast to the anti--HER2 cohort, higher \( \text{ERBB2} \) CN was not significantly associated with longer rwPFS in patients receiving chemotherapy (cohort B, HR, 0.93; 95% CI, 0.73 to 1.20; \( P = .59 \)). Age at advanced diagnosis, practice type, sex, and disease site did not show a statistically significant association with rwPFS in cohort A. Other patient characteristics assessed were also not significantly associated with rwPFS in the chemotherapy cohort (Data Supplement). ECOG performance status at the start of therapy was marginally lower for patients receiving HER2-targeted therapy versus chemotherapy (Table 1), and higher ECOG significantly correlated with worse outcome in trastuzumab-treated patients (Data Supplement). Also, as expected, increasing line number was significantly associated with an increased risk of progression or death in patients receiving chemotherapy.

No single \( \text{ERBB2} \) CN cutoff was identified as an optimal predictor of rwPFS on trastuzumab-based therapy (Data Supplement). To visualize the relationship between \( \text{ERBB2} \) CN and rwPFS, patients in cohort A were divided into five subgroups by quintiles of quantitative \( \text{ERBB2} \) CN. For each increasing CN quartile, median rwPFS increased from 4.5 months for patients with CN 5-9 to 11.0 months for patients with CN > 107 (Fig 3). To assess whether longer rwPFS might have been the result of \( \text{ERBB2} \) CN association with other factor(s), we analyzed the relationship between \( \text{ERBB2} \) CN and multiple covariates in cohort A and saw no significant differences in \( \text{ERBB2} \) CN for disease site, age and stage at advanced diagnosis, sex, ancestry, practice type, co-KRAS mutation, co-EGFR amplification, or co-FGFR1 or FGFR2 amplification (Data Supplement). We did see a suggestive association between PIK3CA mutation and lower \( \text{ERBB2} \) CN (unadjusted \( P = .03 \)). In patients with \( \text{ERBB2} \) amp advGEA treated with first-line trastuzumab, higher \( \text{ERBB2} \) CN was a significant predictor as a continuous variable of longer rwOS (HR, 0.79; 95% CI, 0.64 to 0.97; \( P = .02 \)), although the increasing trend for rwOS by each \( \text{ERBB2} \) CN quintile was not as consistent as that for rwPFS (Data Supplement). Patients with CN 34 approximately 107 had longest median rwOS (20.4 months), whereas patients with CN > 107 had similar median rwOS to other subgroups. We did observe longer rwOS for patients with advGEA positive for HER2 by IHC or FISH treated with first-line trastuzumab with \( \text{ERBB2} \) amplification detected by NGS versus those negative for amplification by NGS (Data Supplement), consistent with existing literature.

**DISCUSSION**

In a large genomic data set of 12,905 GEA cases, \( \text{ERBB2} \) amp was detected in 15% of tissue samples tested using NGS-based CGP, with enrichment in esophageal or GEJ samples relative to gastric samples consistent with published studies. The \( \text{ERBB2} \) amp CN distribution and amplicon size were similar across esophageal or GEJ and gastric subsets, and more focal amplification generally correlated with higher copy gains. We compared a cohort of \( \text{ERBB2} \) amp breast carcinoma samples and observed a similar distribution of \( \text{ERBB2} \) CN gain and amplicon size, as well as correlation between focality and CN. However, more comprehensive pan-tumor analysis is needed to further elucidate the genomics of \( \text{ERBB2} \) amplification across disease subtypes.

In a real-world CGDB, we observed that most patients with \( \text{ERBB2} \) amp detected by CGP received trastuzumab in combination with chemotherapy postreceipt of their genomic test results, whereas those without \( \text{ERBB2} \) amp detected received chemotherapy alone, consistent with current guidelines. However, a smaller subset of \( \text{ERBB2} \) amp
cases received first-line treatment regimens absent of anti-HER2 therapy, which was likely because of relatively low-level ERBB2amp (median CN 7), and in two cases, a prior negative HER2 IHC and/or ISH result. Furthermore, for two of these patients with documented second-line therapy at the time of data cutoff, both received anti-HER2 therapy at that time. We also observed that a small subset of patients without ERBB2amp detected on CGP received chemotherapy in combination with anti-HER2 therapy following CGP report, and in the majority of these cases, the patient had a prior positive HER2 IHC and/or ISH result, despite the generally high reported concordance between IHC and ISH testing for HER2 expression and the CGP methodology used for ERBB2 amplification detection in this study (88%-98%).

Historically, IHC testing for HER2 overexpression has been considered the gold standard and remains so according to published guidelines. However, many testing modalities including NGS for ERBB2amp are now clinically available as validated US Food and Drug Administration–approved assays and studies correlating testing results with clinical outcomes to anti-HER2 therapies are needed. Published data in GEA as well as in colorectal cancer show that borderline positivity for HER2 expression and lower associated levels of ERBB2 amplification are associated with reduced benefit from anti-HER2 therapies. Recent data from our group suggest that patients with GEA with positive IHC and/or ISH results for HER2 expression but negative results for ERBB2amp by NGS have worse outcomes on anti-HER2 therapy compared with patients testing positive by both or multiple methodologies. Further exploratory analysis using median ERBB2 CN as a cutoff suggested that ERBB2 CN can be used effectively to further stratify best responders to anti-HER2 therapy, suggesting additional utility for quantitative NGS testing.

In the current study, we expanded on these analyses and showed that ERBB2 CN is predictive as a continuous variable for efficacy outcome to anti–HER2-targeted therapy in advGEA. Although no single CN cutoff appeared to be clinically optimal, increased rwPFS was observed for
each increase in ERBB2 CN quintile, with a median rwPFS of 5.4 months for patients with ERBB2 CN of 5-9 compared with 11.0 months for patients with ERBB2 CN > 107. We further assessed whether covariates associated with higher ERBB2 CN could actually be driving anti-HER2 therapy outcome; however, none of the covariates assessed were significantly associated with ERBB2 CN in our cohort of patients treated with first-line trastuzumab with the exception of PIK3CA mutations, which were suggestively associated with lower ERBB2 CN (P = .03) and could contribute to anti-HER2 resistance. In our genomic analysis, we also found that higher ERBB2 CN was associated with more focal gene amplification; however, ERBB2 amplicon size itself was not an independent predictor of outcome to anti-HER2 therapy (HR, 1.12; 95% CI, 0.94 to 1.35; P = .21).

Additional RTKs have been shown to be oncogenic drivers, and therapeutic strategies have been implemented targeting overexpression or amplification of EGFR, MET, and FGFR2.27 Historically, IHC and/or ISH methodologies, similar to those approved for HER2, have been used in trials investigating EGFR and MET expression as biomarkers with limited success.28 However, more recently, promising results for MET amplification as a biomarker in NSCLC have been reported, and within the METamp cohort, increased MET CN was further predictive of improved outcome to

### TABLE 1. Characteristics of Patients With ERBB2-Amplified GEA in the Clinicogenomic Database

| Characteristics                  | Cohort A: Anti-HER2 Therapy (first-line only, n = 101) | Cohort B: Chemotherapy Alone (any line, n = 87) |
|----------------------------------|--------------------------------------------------------|--------------------------------------------------|
| Disease site, No. (%)            | 82 (81.2)                                              | 76 (87.4)                                        |
| Esophageal/GEJ                   | 19 (18.8)                                              | 11 (12.6)                                        |
| Gastric                          |                                                        |                                                  |
| Sex, No. (%)                     | 88 (87.1)                                              | 74 (85.1)                                        |
| Male                             | 13 (12.9)                                              | 13 (14.9)                                        |
| Female                           |                                                        |                                                  |
| Stage at diagnosis, No. (%)      | 11 (10.9)                                              | 11 (12.6)                                        |
| I/II                             | 8 (7.92)                                               | 8 (9.20)                                         |
| III                              | 77 (76.2)                                              | 64 (73.6)                                        |
| IV                               | 5 (4.95)                                               | 4 (4.60)                                         |
| Unknown                          |                                                        |                                                  |
| Median age at advanced diagnosis, years (IQR) | 62.0 (56.0-68.0) | 62.0 (55.0-70.0) |
| Ancestry, No. (%)                | 86 (85.1)                                              | 72 (82.7)                                        |
| EUR                              | 10 (9.90)                                              | 12 (13.8)                                        |
| AMR                              | 4 (3.96)                                               | 3 (3.53)                                         |
| Other                            | 1 (0.99)                                               | 0 (3.45)                                         |
| Practice type, No. (%)           | 92 (91.1)                                              | 80 (91.6)                                        |
| Community                        | 9 (8.91)                                               | 7 (8.04)                                         |
| Academic                         |                                                        |                                                  |
| HER2 IHC/FISH status,* No. (%)   | 83 (82.2)                                              | 50 (57.5)                                        |
| Positive                         | 1 (0.99)                                               | 1 (1.15)                                         |
| Equivocal                        | 4 (3.96)                                               | 16 (18.4)                                        |
| Negative                         | 13 (12.9)                                              | 20 (23.0)                                        |
| Unknown                          |                                                        |                                                  |
| ECOG PS at therapy initiation,** No. (%) | 61 (60.4) | 44 (50.6)                                        |
| 0-1                              | 31 (30.7)                                              | 35 (40.2)                                        |
| 2+                               | 9 (8.91)                                               | 8 (9.20)                                         |
| Missing                          |                                                        |                                                  |

Abbreviations: AMR, ad mixed American; CGP, comprehensive genomic profiling; ECOG, Eastern Cooperative Oncology Group; EUR, European; GEA, gastroesophageal adenocarcinoma; GEJ, gastroesophageal junction; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; IQR, interquartile range.

*HER2 IHC/FISH status: from test results within 90 days of CGP specimen collection date.

**The closest ECOG performance status from up to 30 days before the therapy initiation, or up to 7 days after the therapy initiation.
MET-targeted therapy.\textsuperscript{29} Promising studies assessing EGFR amplification as a predictive biomarker in GEA have also been presented.\textsuperscript{30} Finally, innovative trial designs have been implemented in which personalized antibody therapy was selected and prioritized on the basis of presence and degree of gene amplification.\textsuperscript{31} These data suggest that the observations made herein for ERBB2 in GEA may potentially be applicable to other RTKs and disease subtypes.

Limitations of this study include absence of clinical information and treatment history for most patients in the FMI genomic database. For the CGDB cohort, clinical data were derived from EHR and data not documented in the EHR may be incomplete or missing, particularly for events occurring outside of the FH network. rwPFS was defined as time from therapy start to progression or death, where rwP events are abstracted from EHR and are limited by clinician interpretation and documentation. Selection bias is likely also present due to all patients in this study having received CGP. Additional retrospective and prospective analyses to assess quantitative ERBB2 CN as a more sensitive predictive biomarker in GEA, and potentially in other tumor types, are needed.

In conclusion, in patients with advGEA treated with first-line trastuzumab, quantitative ERBB2 CN was a significant predictor of efficacy outcome to anti-HER2 therapy, where higher CN was associated with longer rwPFS. These data along with results of prior studies suggest that although traditional IHC and ISH methodologies for detection of HER2 expression are generally concordant, NGS-based methodologies to detect and quantify ERBB2 copy gains may allow for more robust stratification of HER2-positive patients and better prediction of efficacy benefit from approved and investigational HER2-targeted therapies. Ultimately, in caring for patients, we seek to gather maximal data to inform prognostic and predictive clinical abilities and feel our data suggest that quantitative ERBB2 CN information may help extend these goals in ERBB2amp GEA.

FIG 3. ERBB2 CN as a predictor of rwPFS in patients with advanced GEA treated with anti-HER2 therapy in the first-line setting. Association of ERBB2 CN with rwPFS in patients with GEA treated with first-line trastuzumab in the CGDB. ERBB2 CN was predictive as a continuous variable, and no single CN cutoff was identified as an optimal predictor of rwPFS. To visualize Kaplan-Meier rwPFS curves, the cohort was split into ERBB2 CN quintiles. Curves are truncated at 30 months as the number at risk was reduced to one in the entire ERBB2 amp cohort. Median and IQR rwPFS for each CN quintile is shown. CGDB, clinicogenomic database; CN, copy number; GEA, gastroesophageal adenocarcinoma; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; rwPFS, real-world progression-free survival.

| CN Range | Median rwPFS (95% CI) |
|----------|-----------------------|
| 5-9      | 11.0 months (6.3 to 19.4) |
| 10-16    | 9.0 months (6.0 to 15.5)   |
| 17-34    | 8.8 months (6.9 to 12.3)   |
| 35-107   | 7.1 months (6.1 to 11.3)   |
| > 107    | 5.4 months (4.5 to 10.7)   |

| No. at risk: | 5-9 | 10-16 | 17-34 | 35-107 | > 107 |
|-------------|-----|-------|-------|--------|-------|
| 5-9         | 18  | 7     | 3     | 0      | 0     |
| 10-16       | 21  | 15    | 3     | 1      | 0     |
| 17-34       | 21  | 14    | 5     | 1      | 0     |
| 35-107      | 20  | 14    | 8     | 3      | 1     |
| > 107       | 21  | 18    | 9     | 7      | 2     |

**AFFILIATIONS**
1Foundation Medicine, Boston, MA
2Flatiron Health, New York, NY
3Massachusetts General Hospital Cancer Center, Boston, MA

**CORRESPONDING AUTHOR**
Alexa B. Schrock, PhD, Foundation Medicine, Inc, 1 Marina Park Drive, Floor 12, Boston, MA 02210; e-mail: aschrock@foundationmedicine.com.

**PRIOR PRESENTATION**
Presented in part as a poster at the ASCO 2021 Annual Meeting.

**SUPPORT**
Supported by Foundation Medicine, Inc.

**DATA SHARING STATEMENT**
All data relevant to the study are included in the article or uploaded in the Data Supplement.

**AUTHOR CONTRIBUTIONS**
Conception and design: Liangliang Zhang, Omar Hamdani, Ole Gjoerup, Cheryl Cho-Phan, Jeremy Snider, Garrett Frampton, Jeffrey M. Venstrom, Alexa B. Schrock
REFERENCES
1. Indini A, Rijavec E, Grossi F: Trastuzumab deruxtecan: Changing the destiny of HER2 expressing solid tumors. Int J Mol Sci 22:4774, 2021
2. Meric-Bernstam F, Johnson AM, Dumbrava EEI, et al: Advances in HER2-targeted therapy: Novel agents and opportunities beyond breast and gastric cancer. J Clin Cancer Res 25:2033-2041, 2019
3. Moasser MM: The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26:6469-6487, 2007
4. Shitara K, Baba E, Fujitani K, et al: Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer 24:780-789, 2021
5. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
6. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, pacitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792, 2006
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 in metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
8. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376:687-697, 2010
9. Dumbrava EEI, Balasi K, Raghw K, et al: Targeting ERBB2 (HER2) amplification identified by next-generation sequencing in patients with advanced or metastatic solid tumors beyond conventional indications. JCO Precis Oncol 3:1-12, 2019
10. Javle M, Borad MJ, Azad NS, et al: Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): A multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22:1290-1300, 2021
11. Nowak JA: HER2 in colorectal carcinoma: Are we there yet? Surg Pathol Clin 13:485-502, 2020
12. Catenacci DVT, Liao WL, Zhao L, et al: Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH. Gastric Cancer 19:1066-1079, 2016
13. Janjigian YY, Sanchez-Vega F, Jonsson P, et al: Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov 8:49-58, 2018

14. Ross DS, Zehir A, Cheng DT, et al: Next-generation assessment of human epidermal growth factor receptor 2 (ERBB2) amplification status: Clinical validation in the context of a hybrid capture-based, comprehensive solid tumor genomic profiling assay. J Mol Diagn 19:244-254, 2017

15. Stein SM, Snider J, Ali SM, et al: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncol 17:4101-4114, 2021

16. Liu Z, Shi M, Li X, et al: HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma. J Cancer Res Clin Oncol 147:1315-1324, 2021

17. Gomez-Martin C, Plaza JC, Pazo-Cid R, et al: Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol 31:4445-4452, 2013

18. Frampton GM, Fichtenholtz A, Cheng DT, et al: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31:1023-1031, 2013

19. US Food and Drug Administration: PMA P170019/S006: FDA summary of safety and effectiveness data. www.accessdata.fda.gov/cdrh_docs/pdf17/P170019S006B.pdf

20. Singal G, Miller PG, Agarwala V, et al: Association of patient characteristics and tumor genomics with clinical outcomes among patients with non-small cell lung cancer using a clinigenomic database. JAMA 321:1391-1399, 2019

21. Birmbaum B, Nussbaum N, Seidl-Rathkopf K, et al: Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. arXiv. 2001.09765, 2020

22. Griffith SD, Miksad RA, Calkins G, et al: Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small-cell lung cancer data set. JCO Clin Cancer Inform 3:1-13, 2019

23. Griffith SD, Tucker M, Bowser B, et al: Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer. Adv Ther 36:2122-2136, 2019

24. Van Cutsem E, Bang YJ, Feng-Yi F, et al: HER2 screening data from ToGA: Targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18:476-484, 2015

25. Hafrer I, Schierle K, Raimundez E, et al: HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: Results from the prospective multicenter VARIANZ study. J Clin Oncol 39:1468-1478, 2021

26. Sartore-Bianchi A, Trusolino L, Martino C, et al: Dual-targeted therapy with trastuzumab and laptitinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 17:738-746, 2016

27. Wainberg ZA, Enzinger PC, Kang Y-K, et al: Randomized double-blind placebo-controlled phase 2 study of bemantuzumab combined with modified FOLFOX6 (nFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT). J Clin Oncol 39, 2021 (suppl 3; abstr 160)

28. Drikos A, Cappuzzo F, Ou SI, et al: Targeting MET in lung cancer: Will expectations finally be MET? J Thorac Oncol 12:15-26, 2017

29. Wolf J, Seto T, Han JY, et al: Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer. N Engl J Med 383:944-957, 2020

30. Maron SB, Alpert L, Kwak HA, et al: Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov 8:696-713, 2018

31. Catanacci DVT, Moya S, Lomnicki S, et al: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov 11:308-325, 2021